cas 403-01-0, 3-FLUORO-4-HYDROXY-BENZOIC ACID METHYL ESTER

Articles about 403-01-0Total 25 be found

Article title
Article abstract
Author
Journal number and time
Download

Sequential Ir/Cu-Mediated Method for the Meta-Selective C-H Radiofluorination of (Hetero)Arenes
This article describes a sequential Ir/Cu-mediated process for the meta-selective C-H radiofluorination of (hetero)arene substrates. In the first step, Ir-catalyzed C(sp2)-H borylation affords (hetero)aryl pinacolboronate (BPin) esters. The intermediate organoboronates are then directly subjected to copper-mediated radiofluorination with [18F]tetrabutylammonium fluoride to afford fluorine-18 labeled (hetero)arenes in high radiochemical yield and radiochemical purity. This entire process is performed on a benchtop without Schlenk or glovebox techniques and circumvents the need to isolate (hetero)aryl boronate esters. The reaction was automated on a TracerLab FXFN module with 1,3-dimethoxybenzene and a meta-tyrosine derivative. The products, [18F]1-fluoro-3,5-dimethoxybenzene and an 18F-labeled meta-tyrosine derivative, were obtained in 37 ± 5% isolated radiochemical yield and >99% radiochemical purity and 25% isolated radiochemical yield and 99% radiochemical purity, and 0.52 Ci/μmol (19.24 GBq/μmol) molar activity (Am), respectively.
Wright, Jay S.,Sharninghausen, Liam S.,Preshlock, Sean,Brooks, Allen F.,Sanford, Melanie S.,Scott, Peter J. H.
supporting information
p. 6915 - 6921
(2021/05/29)

TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS
Disclosed are a series of compounds or their tautomers having a general structure represented by Formula la or lb and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula la or lb compounds or tautomers or pharmaceutically acceptable salts thereof.
-
Page/Page column 144

(2021/04/23)

Phenol compound ortho-position direct fluorination method
The invention relates to a phenol compound ortho-position direct fluorination method which comprises the following steps: reacting a phenol compound shown in a formula (1A) with a fluorination reagentin a solvent under the action of a photocatalyst and a light source at room temperature, and separating and purifying a reaction mixture after the reaction to obtain a fluorinated phenol compound shown in a formula (2A). The advantages are as follows: the method for directly fluorinating phenol by organic photocatalysis is simple in operation process; raw materials are commercialized and easy toobtain; the photocatalyst is low in price, easy to obtain and environmentally friendly; the reaction condition is mild; the site selectivity is high; the reaction is efficient; and a fluorinated phenol derivative can be prepared only through one step.
-
Paragraph 0073-0075

(2020/04/17)

Compositions and methods for treating cancer
The invention provides a protected anti-neoplastic agent of the formula Hyp-N, wherein N is an anti-neoplastic agent and a protectable hydroxyl group of the anti-neoplastic is substituted with Hyp; Hyp is a moiety having the formula: wherein R 2 is hydrogen; R 3 is hydrogen or C 1 -C 6 alkyl; R 1 is C 1 -C 6 alkyl or C 1 -C 6 alkoxy, optionally substituted with one or more heteroatom-containing groups; and R 4 is hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy, optionally substituted with one or more heteroatom-containing groups.
-
Paragraph 0219; 0228

(2019/10/16)

Photoinduced Hydroxylation of Organic Halides under Mild Conditions
Presented in this paper is photoinduced hydroxylation of organic halides, providing a mild access to a range of functionalized phenols and aliphatic alcohols. These reactions generally proceed under mild reaction conditions with no need for a photocatalyst or a strong base and show a wide substrate scope as well as excellent functional group tolerance. This work highlights the unique role of NaI that allows a challenging transformation to proceed under mild reaction conditions.
Cai, Yue-Ming,Xu, Yu-Ting,Zhang, Xin,Gao, Wen-Xia,Huang, Xiao-Bo,Zhou, Yun-Bing,Liu, Miao-Chang,Wu, Hua-Yue
supporting information
p. 8479 - 8484
(2019/10/16)

Synthesis and Mesomorphic Properties of Novel Bent-shaped Naphthyl Diketones
The synthesis and liquid-crystalline properties are reported for novel naphthyl-based diketones incorporating variant terminal chains and lateral fluoro- substitution. Newly prepared materials exhibit a broad temperature range of the nematic phase. The study demonstrates how subtle structural modifications can be exploited to alter the efficiency of molecular packing and consequently the thermal behaviour.
Buljan, An?ela,Kne?evi?, Anamarija,Dokli, Irena,Lesac, Andreja
p. 173 - 179
(2019/12/12)

Imidazole-containing condensed tricyclic compound and application thereof
The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.
-
Paragraph 0140

(2018/03/01)

1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2
The present invention relates to novel compounds that inhibit Lp‐PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases or disorders associated with the activity of Lp‐PLAs
-
Page/Page column 40

(2016/02/18)

Novel fluorinated ferroelectric organosiloxane liquid crystals
A progress report on the synthesis and characterisation of a series of fluorinated chiral bi-mesogen low molar mass organosiloxane materials is presented. The mesogenic moiety is identical to that in the TSiKN65F mono-mesogen material reported by Naciri et al., which displays a de Vries-type SmA* phase. The parameter varied across the series is the length of the alkyl chain linking the mesogen moiety to the siloxane. The material with 10 carbon atoms in the chains displays a stable smectic phase with ferroelectric response at room temperature, whereas the materials with 6, 7 and 8 carbon atoms tend to crystallize. Copyright Taylor & Francis Group, LLC.
Zoghaib,Carboni,George,Al-Manthari,Al-Hussaini,Al-Futaisi
scheme or table
p. 123 - 131
(2012/01/12)

SPIROCYCLIC GPR40 MODULATORS
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also
-
Page/Page column 155

(2010/04/30)

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS
The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can a
-
Page/Page column 58

(2010/04/03)

SYNTHESIS OF PYRAZOLES
The present invention provides methods of making HCl salts, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other
-
Page/Page column 42

(2009/08/16)

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
-
Page/Page column 227-228

(2009/10/22)

HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE
To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.
-
Page/Page column 227

(2009/02/10)

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS
The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.
-
Page/Page column 42; 43; 119-120

(2008/12/07)

Hypoxia-Activated Anti-Cancer Agents
Prodrugs of cyclic anthracyclin toxins comprising a hypoxia-activated trigger and are disclosed. In addition, methods of treating cancer using the compounds of the invention are disclosed.
-
Page/Page column 26

(2008/12/05)

Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.
-
Page/Page column 35

(2010/11/28)

IMIDAZOPYRIDINE COMPOUND
The present invention provides an imidazopyridine compound represented by formula (I), wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents -(CH2)m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.
-
Page/Page column 37

(2008/06/13)

Ester derivatives and medicinal use thereof
The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.
-
Page/Page column 39

(2010/11/08)

Electrophilic fluorination with N,N′-difluoro-2,2′-bipyridinium salt and elemental fluorine
NNpm-Difluoro-22pm-bipyridiniu m bis(tetrafluoroborate) (MEC-31) was shown to be a highly reactive electrophilic fluorinating agent with the highest effective fluorine content in its class. We have developed the perfect recycled fluorination system with MEC-31 for the lower-cost industrial fluorination and for an environment. MEC-31 can be completely recycled including the counter-anion. We found the fluorination of 2-naphthol in liquid CO2 with MEC-31 in the presence of catalytic amount of NaOTf proceeded quantitatively without the generation of by-product. In the fluorination of 1,3-dicarbonyl compounds with elemental fluorine, we found the introduction method of fluorine gas would be very important in order to make a reaction efficient. As fluorination goes on, the quantity of 1,3-dicarbonyl compounds of the starting material is reduced gradually, and therefore the quantity of fluorine must be reduced by the method to control the flow rate or the concentration of fluorine gas diluted with nitrogen, together the fluorination to proceed efficiently.
Adachi, Kenji,Ohira, Yutaka,Tomizawa, Ginjiro,Ishihara, Sumi,Oishi, Satoshi
p. 173 - 183
(2007/10/03)

Elemental fluorine Part 12. Fluorination of 1,4-disubstituted aromatic compounds
Direct fluorination of a series of 1,4-disubstituted benzene derivatives in acid reaction media at convenient temperature leads, in many cases, to selectively fluorinated aromatic products in preparatively useful conversions and yields.
Chambers, Richard D.,Hutchinson, John,Sparrowhawk, Matthew E.,Sandford, Graham,Moilliet, John S.,Thomson, Julie
p. 169 - 173
(2007/10/03)

Fluorination process
According to the present invention there is provided a process for the selective introduction of one or more fluorine atoms into a disubstituted aromatic compound in an acid medium with fluorine gas characterized in that the acid medium has a dielectric constant of at least 20 and a pH of less than 3. The present process provides a cost effective means of selectively introducing one or more fluorine atoms into an aromatic compound in good overall yield.
-
(2008/06/13)

Use of 19F NMR spectroscopy to evaluate reactions in solid phase organic synthesis
Gel-phase 19F NMR spectroscopy has been used to characterize products from a variety of reactions of fluorinated aromatics linked to a TentaGel resin. High quality spectra were obtained in a few minutes using an ordinary NMR spectometer, and the 19F chemical shifts of the support-bound compounds closely matched those of soluble references. In addition, substantial chemical shift differences were obtained for almost all of the synthetic transformations, illustrating the potential of 19F NMR for rapid monitoring of reactions in solid-phase organic synthesis.
Svensson, Anette,Fex, Tomas,Kihlberg, Jan
p. 7649 - 7652
(2007/10/03)

Mesomorphic compound, liquid crystal composition containing same and liquid crystal device using same
A mesomorphic compound represented by the following formula (I): STR1 wherein R1 and R2 respectively denote a linear or branched alkyl group having 1-18 carbon atoms capable of including one or non-neighboring two or more methylene g
-
(2008/06/13)

Power and structure-variable fluorinating agents. The N-fluoropyridinium salt system
The usefulness of the N-fluoropyridinium salt system as a source of fluorinating agents was examined by using substituted or unsubstituted N-fluoropyridinium triflates 1-11, N-fluoropyridinium salts possessing other counteranions 1a-d and 3a, and the counteranion-bound salts, N-fluoropyridinium-2-sulfonates 12 and 13. Electrophilic fluorinating power was found to vary remarkably according to the electronic nature of the ring substituents. This power increased as the electron density of positive nitrogen sites decreased, and this was correlated to the pKa values of the corresponding pyridines. By virtue of this variation, it was possible to fluorinate a wide range of nucleophilic substrates differing in reactivity. It is thus possible to fluorinate aromatics, carbanions, active methylene compounds, enol alkyl or silyl ethers, vinyl acetates, ketene silyl acetals, and olefins through the proper use of salts pentachloro 6 through 2,4,6-trimethyl 2, their power decreasing in this order. All the reactions could be explained on the basis of a one-electron-transfer mechanism. N-Fluoropyridinium salts showed high chemoselectivity in fluorination, the extent depending on the reactive moiety. In consideration of these Findings, selective 9α-fluorination of steroids was carried out by reacting 1 with tris(trimethylsilyl ether) 73 of a triketo steroid. Regio- or stereoselectivity in fluorination was determined by a N-fluoropyridinium salt structure. Steric bulkiness of the N-F surroundings hindered the ortho fluorination of phenols and aniline derivatives, while the capacity for hydrogen bonding on the part of the counteranions prompted this process, and the counteranion-bound salts 12 and 13 underwent this fluorination exclusively or almost so. Both bulky N-fluoropyridinium triflates 2 and 7 preferentially attacked the 6-position of the conjugated vinyl ester of a steroid from the unhindered β-direction to give a thermally unstable 6β-fluoro isomer. On the basis of these results, N-fluoropyridinium salts may be concluded to constitute a system that can serve as a source of the most ideal fluorinating agents for conducting desired selective fluorination through fluorinating capacity or structural alteration.
Umemoto, Teruo,Fukami, Shinji,Tomizawa, Ginjiro,Harasawa, Kikuko,Kawada, Kosuke,Tomita, Kyoichi
p. 8563 - 8575
(2007/10/02)